# DESCRIPTION

## FIELD OF THE INVENTION

- introduce human antibodies

## RELATED ART

- motivate influenza A virus
- describe current vaccines
- limitations of current vaccines
- motivate M2 protein as target
- describe M2 protein
- motivate passive immunization

## SUMMARY OF THE INVENTION

- introduce library-based screening
- identify and isolate scFv
- generate fully human IgG1 antibodies
- describe advantages of human antibodies
- describe CDR sequences
- distinguish LCVR and HCVR types
- describe abundance of combinations
- describe high affinity towards M2e antigen
- describe epitope mapping
- describe binding to different M2 variants
- describe binding to cell-associated M2
- describe binding to M2 in virus particles
- describe therapeutic activity in mouse model
- describe single dose administration
- introduce monoclonal antibody
- describe LCVR and HCVR
- describe antigen binding site
- describe pharmaceutical composition

## DETAILED DESCRIPTION OF THE INVENTION

- define antibody
- describe antibody structure
- specify antibody classes
- define recognizing
- explain Fv
- describe single chain antibody
- specify single chain antibody structure
- define diabody
- describe diabody structure
- define human antibody
- specify human antibody sequence
- describe human antibody differences
- define fully human antibody
- explain fully human antibody advantages
- describe human antibody regions
- specify human antibody constant regions
- define monoclonal antibody
- explain constant region
- describe light chain constant region
- describe heavy chain constant region
- define variable region
- specify variable region structure
- describe human variable region
- specify human variable region sequence
- describe complementarity determining regions
- explain variable region framework
- describe light chain variable region
- specify human kappa light chain variable region
- define lambda LCVRs
- describe structure of lambda LCVRs
- define HCVRs
- describe structure of HCVRs
- define CDR
- define antigen
- define extracellular domain of influenza A virus M2 protein
- define influenza M2e antigen
- describe conjugates of influenza M2e antigen
- describe fusion proteins of influenza M2e antigen
- describe virus particles of influenza M2e antigen
- define specifically binding
- describe determination of Kd by Friguet ELISA
- describe determination of Kd by ELISA
- describe determination of Kd by Biacore analysis
- describe determination of EC50 by ELISA
- define effective amount
- describe therapeutic treatment of human
- define tag
- describe purification or detection tag
- list examples of tags
- describe haemagglutinin tag
- describe myc tag
- describe poly-histidine tag
- describe protein A
- describe glutathione S transferase
- describe Glu-Glu affinity tag
- describe substance P
- describe FLAG peptide
- describe streptavidin binding peptide
- describe other antigenic epitope or binding domain
- reference U.S. Ser. No. 06686168
- introduce library-based screening method
- describe monoclonal antibody
- specify human monoclonal antibody
- describe CDRs of HCVRs and LCVRs
- identify clonally related antibodies
- specify monoclonal antibody composition
- describe LCVR composition
- describe HCVR composition
- specify antigen binding site
- describe further preferred embodiments
- specify LCVR and HCVR combinations
- describe sequence similarities
- specify LCVR groups
- describe LCVR and HCVR compositions
- specify further embodiments
- describe LCVR and HCVR compositions
- specify further embodiments
- describe LCVR and HCVR compositions
- specify further embodiments
- identify different types of LCVRs
- specify preferred LCVRs
- describe most abundant combinations
- specify very preferred LCVRs
- describe removal of cloning artifacts
- specify preferred LCVR compositions
- describe preferred embodiments of LCVR
- specify HCVR types
- describe most abundant HC CDR combination
- replace cloning artifacts in HCVRs
- describe HCVR amino acid sequences
- identify LC CDR and HC CDR combinations
- specify very preferred LC CDR and HC CDR sequences
- describe very preferred LC CDR and HC CDR sequences
- describe very preferred LC CDR and HC CDR sequences
- describe very preferred LC CDR and HC CDR sequences
- describe very preferred LC CDR and HC CDR sequences
- describe preferred LCVR and HCVR amino acid sequences
- describe very preferred LCVR and HCVR amino acid sequences
- describe preferred antigen binding site embodiments
- describe preferred antigen binding site embodiments
- describe further preferred antigen binding site embodiments
- define monoclonal antibody
- specify LCVR and HCVR
- specify identity of LCVR and HCVR to SEQ ID NOs
- specify preferred embodiments of LCVR and HCVR
- specify recombinant production of monoclonal antibody
- specify formats of monoclonal antibody
- specify preferred embodiments of monoclonal antibody
- specify IgG1 and human IgG1
- specify kappa LC and gamma 1 HC
- specify preferred embodiments of kappa LC and gamma 1 HC
- specify binding of monoclonal antibody to influenza M2e antigen
- specify epitope of influenza M2e antigen
- specify preferred embodiments of influenza M2e antigen
- specify dissociation constant of monoclonal antibody and influenza M2e antigen
- specify preferred embodiments of dissociation constant
- specify further preferred embodiments of dissociation constant
- specify still further preferred embodiments of dissociation constant
- specify most preferred embodiments of dissociation constant
- specify further preferred embodiments of monoclonal antibody
- specify still further preferred embodiments of monoclonal antibody
- specify most preferred embodiments of monoclonal antibody
- specify further preferred embodiments of LCVR and HCVR
- specify still further preferred embodiments of LCVR and HCVR
- specify most preferred embodiments of LCVR and HCVR
- specify further preferred embodiments of monoclonal antibody and influenza M2e antigen
- specify still further preferred embodiments of monoclonal antibody and influenza M2e antigen
- specify most preferred embodiments of monoclonal antibody and influenza M2e antigen
- specify epitope mapping
- specify minimal epitope recognized by monoclonal antibody
- specify recognition of variants of epitope
- specify further preferred embodiments of antigen binding site
- specify still further preferred embodiments of antigen binding site
- specify most preferred embodiments of antigen binding site
- specify further preferred embodiments of LCVR and HCVR
- specify still further preferred embodiments of LCVR and HCVR
- specify most preferred embodiments of LCVR and HCVR
- specify further preferred embodiments of monoclonal antibody
- specify still further preferred embodiments of monoclonal antibody
- specify most preferred embodiments of monoclonal antibody
- specify further preferred embodiments of antigen binding site
- specify most preferred embodiments of antigen binding site
- describe monoclonal antibody embodiments
- specify antigen binding site
- describe LCVR and HCVR
- detail LCVR and HCVR sequences
- describe chain shuffling method
- cite references for chain shuffling
- describe LCVR of monoclonal antibody
- specify LCVR sequences
- describe HCVR of monoclonal antibody
- specify HCVR sequences
- describe preferred embodiments of LCVR and HCVR
- describe nucleic acid molecule encoding HCVR or LCVR
- specify nucleic acid molecule sequences
- describe expression vector for recombinant expression
- specify expression vector sequences
- describe host cell comprising nucleic acid molecule or expression vector
- specify host cell types
- describe monoclonal antibody for use as pharmaceutical
- describe pharmaceutical composition
- specify pharmaceutical composition components
- describe method of passive immunization
- specify administration techniques
- describe method of treating influenza A virus infection
- describe method of preventing influenza A virus infection
- describe monoclonal antibody for use in passive immunization
- describe monoclonal antibody for use in treatment and/or prophylaxis
- describe use of monoclonal antibody in medicament manufacture
- describe monoclonal antibody for use in treating or preventing influenza A virus infection
- describe use of antibody in detection of influenza A virus M2 protein
- describe further aspects of the invention
- describe pharmaceutical composition administration
- describe pharmaceutical composition components
- describe method of passive immunization
- describe method of treating influenza A virus infection
- describe method of preventing influenza A virus infection
- describe use of monoclonal antibody in medicament manufacture

### EXAMPLE 1

- isolate PBMC from blood
- stain cells with M2e peptide and antibodies
- sort M2e-specific B cells
- construct scFv cell surface display library

### EXAMPLE 2

- perform RT-PCR on BHK cells
- clone scFv coding regions into expression vector
- transfect HEK-293T cells with scFv-Fc fusion constructs
- perform ELISA analysis for M2e-specific binding
- monitor scFv-Fc expression levels
- sequence ELISA-positive clones

### EXAMPLE 3

- express and purify scFv-msFcγ2c fusion proteins
- clone scFv coding regions into expression vector
- transfect HEK-293T cells with scFv-msFcγ2c fusion constructs
- purify scFv-msFcγ2c fusion proteins by protein A-sepharose chromatography
- analyze protein-containing fractions by SDS-PAGE

### EXAMPLE 4

- perform ELISA analysis of scFv-msFcγ2c fusion protein binding
- coat ELISA plates with M2e conjugated to RNAse A
- incubate plates with serial dilutions of scFv-msFcγ2c fusion proteins
- detect bound scFv-Fc fusion proteins with HRPO-labeled antibody
- perform competition ELISA with M2-derived peptides
- analyze binding of scFv-msFcγ2c fusion proteins to M2-derived peptides

### EXAMPLE 5

- analyze binding of scFv-msFcγ2c fusion proteins to M2-expressing L929 cells
- detect bound antibodies with Cy5-labeled goat anti-mouse antibody

### EXAMPLE 6

- inject mice with scFv-msFcγ2c fusion proteins or mouse IgG
- infect mice with lethal dose of Influenza A virus
- monitor weight loss and fever
- analyze protective effect of scFv-msFcγ2c fusion proteins
- determine minimal amount of antibody required for protection

### EXAMPLE 7

- infect mice with lethal dose of Influenza A virus
- inject mice with scFv-D005-msFcγ2c at different time points
- analyze therapeutic activity of scFv-D005-msFcγ2c

### EXAMPLE 8

- construct expression vectors for fully human M2-specific IgG1
- express and purify fully human IgG1
- analyze fully human IgG1

### EXAMPLE 9

- introduce binding of IgG1-D005 to M2-expressing 293T cells
- transfect 293T cells with M2 protein or M2-VN/PR fusion protein
- analyze reactivity of IgG1-D005 with transfected cells
- incubate cells with IgG1-D005 and detect bound antibodies
- analyze fluorescence intensity by flow cytometry
- determine EC50 of IgG1-D005 binding to M2-PR and M2-VN/PR
- introduce EXAMPLE 10
- analyze prophylactic activity of IgG1-D005 in mouse model
- test IgG1-D005 and scFv-D005-msFcγ2c in mouse model
- investigate involvement of ADCC
- use scFv-D005-hFcm to test Fc receptor interaction
- inject mice with IgG1-D005, scFv-D005-msFcγ2c, or scFv-D005-hFcm
- infect mice with Influenza A virus
- monitor weight loss and fever
- compare prophylactic activity of IgG1-D005 and scFv-D005-msFcγ2c
- introduce EXAMPLE 11
- determine affinities of antibodies by Friguet-ELISA
- incubate antibodies with RNAse-M2e conjugate
- detect bound antibodies by ELISA
- determine Kd values of antibodies
- repeat assay with free M2e peptide

